» Articles » PMID: 24978037

Role of Anti-vimentin Antibodies in Renal Transplantation

Overview
Journal Transplantation
Specialty General Surgery
Date 2014 Jul 1
PMID 24978037
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The role of non-HLA antibodies in rejection is not clear. We investigate whether antibodies to vimentin are made after renal transplantation and if production is associated with interstitial fibrosis and tubular atrophy (IFTA).

Methods: In this retrospective study, sera from 70 recipients of renal allografts (40 controls, 30 IFTA) were studied. The biopsy diagnosis of interstitial fibrosis and tubular atrophy (IFTA) was based on random, cause-indicating biopsies. Sera were collected pretransplant and at 3 monthly intervals up to 5 years posttransplant or diagnosis of IFTA and assayed by ELISA for IgM and IgG anti-vimentin antibodies (AVA) and HLA antibodies.

Results: Mean titers of IgM AVA were higher at every year after transplantation compared with pretransplant for both IFTA and controls groups (P<0.001). There was no difference in the mean level of IgM AVA achieved by IFTA and control groups. The mean pretransplant levels of IgG AVA in the IFTA and control group were 18.2±11.7 and 11.0±8.1, respectively (P=0.001). There was a significant increase between the pretransplant mean levels of IgG AVA and the levels at years 1 to 4 in the IFTA group (years 1-3, P<0.0001, year 4 P=0.003) but not in the controls. There was no significant difference between the numbers of IFTA or control patients achieving a positive value (mean+2SD of pretransplant antibody titers) of IgM AVA (50% versus 37.5%, respectively) or IgG AVA (26.6% versus 12.5%, respectively). There was no association between production of HLA and AVA antibodies.

Conclusion: Posttransplant production of IgM AVA is not associated with IFTA. The production of IgG AVA by a minority of IFTA patients suggests that in some individuals, IgG AVA may be involved in the pathology of IFTA.

Citing Articles

Evaluating the Clinical Relevance of Antibodies against Non-Human Leukocyte Antigen in Kidney Transplantation.

Bhutani S, Harris S, Carr M, Russell-Lowe M, Worthington J, Wu H Antibodies (Basel). 2024; 13(2).

PMID: 38920968 PMC: 11201104. DOI: 10.3390/antib13020044.


Complement component C3 and C5b-9 deposition on hypoxia reperfused endothelial cells by non-HLA antibodies against RhoGDI2: A player involved in graft failure?.

Kardol-Hoefnagel T, Michielsen L, Ehlers A, van Zuilen A, Luijk B, Otten H HLA. 2022; 101(2):103-114.

PMID: 36266772 PMC: 10091817. DOI: 10.1111/tan.14858.


Vascular rejection in cardiac allograft vasculopathy: Impact on graft survival.

Nair N Front Cardiovasc Med. 2022; 9:919036.

PMID: 35990962 PMC: 9386065. DOI: 10.3389/fcvm.2022.919036.


Non-HLA Antibodies and Epitope Mismatches in Kidney Transplant Recipients With Histological Antibody-Mediated Rejection.

Crespo M, Llinas-Mallol L, Redondo-Pachon D, Butler C, Gimeno J, Perez-Saez M Front Immunol. 2021; 12:703457.

PMID: 34305943 PMC: 8300190. DOI: 10.3389/fimmu.2021.703457.


Association between transplant glomerulopathy and graft outcomes following kidney transplantation: A meta-analysis.

Kovacs G, Devercelli G, Zelei T, Hirji I, Voko Z, Keown P PLoS One. 2020; 15(4):e0231646.

PMID: 32343692 PMC: 7188300. DOI: 10.1371/journal.pone.0231646.